<DOC>
	<DOCNO>NCT00095238</DOCNO>
	<brief_summary>The purpose clinical research study learn Irbesartan superior placebo reduce mortality cardiovascular morbidity subject heart failure preserve systolic function . The safety treatment also study .</brief_summary>
	<brief_title>Irbesartan Heart Failure With Preserved Systolic Function ( I-Preserve )</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Irbesartan</mesh_term>
	<criteria>Male female age &gt; = 60 year current symptom heart failure consistent New York Heart Association ( NYHA ) class IIIV Left ventricular ejection fraction ( LVEF ) &gt; = 45 % Willing provide write informed consent AND hospitalization heart failure within past 6 month OR various abnormality electrocardiogram , echocardiogram chest xray indicate heart disease . Acute myocardial infarction within 3 month ; Heart revascularization procedure within 3 month ; Hospitalization angina within 3 month ; Other heart surgery Lifethreatening uncontrolled arrhythmia Subjects implantable cardioverterdefibrillator discharge past 3 month ; Stroke surgery artery brain within 3 month ; Serious lung disease require use home oxygen . Significantly low blood pressure Significantly high blood pressure Other know disease may limit life expectancy &lt; 3 year ; Known suspect bilateral kidney artery narrowing ; Geographic social factor make study participation followup impractical .</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>